ID   NLRX1_RAT               Reviewed;         973 AA.
AC   Q5FVQ8;
DT   24-JUL-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2005, sequence version 1.
DT   24-JUL-2024, entry version 117.
DE   RecName: Full=NLR family member X1;
DE   Flags: Precursor;
GN   Name=Nlrx1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Participates in antiviral signaling. Acts as a negative
CC       regulator of MAVS-mediated antiviral responses, through the inhibition
CC       of the virus-induced RLH (RIG-like helicase)-MAVS interaction. Instead,
CC       promotes autophagy by interacting with TUFM and subsequently recruiting
CC       the autophagy-related proteins ATG5 and ATG12. Regulates also MAVS-
CC       dependent NLRP3 inflammasome activation to attenuate apoptosis. Has no
CC       inhibitory function on NF-kappa-B signaling pathway, but enhances NF-
CC       kappa-B and JUN N-terminal kinase dependent signaling through the
CC       production of reactive oxygen species (By similarity). Regulates viral
CC       mediated-inflammation and energy metabolism in a sex-dependent manner.
CC       In females, prevents uncontrolled inflammation and energy metabolism
CC       and thus, may contribute to the sex differences observed in infectious
CC       and inflammatory diseases (By similarity).
CC       {ECO:0000250|UniProtKB:Q3TL44, ECO:0000250|UniProtKB:Q86UT6}.
CC   -!- SUBUNIT: Homohexamer (By similarity). Interacts with MAVS (By
CC       similarity). Interacts with TUFM (By similarity).
CC       {ECO:0000250|UniProtKB:Q86UT6}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane
CC       {ECO:0000250|UniProtKB:Q86UT6}.
CC   -!- DOMAIN: The LRRCT domain mediates homodimerization and LRRNT mediates
CC       trimerization of the dimers. {ECO:0000250|UniProtKB:Q86UT6}.
CC   -!- SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC089834; AAH89834.1; -; mRNA.
DR   RefSeq; NP_001020181.1; NM_001025010.1.
DR   AlphaFoldDB; Q5FVQ8; -.
DR   SMR; Q5FVQ8; -.
DR   STRING; 10116.ENSRNOP00000071934; -.
DR   iPTMnet; Q5FVQ8; -.
DR   PhosphoSitePlus; Q5FVQ8; -.
DR   jPOST; Q5FVQ8; -.
DR   PaxDb; 10116-ENSRNOP00000011620; -.
DR   Ensembl; ENSRNOT00000077958.2; ENSRNOP00000071934.2; ENSRNOG00000052386.2.
DR   Ensembl; ENSRNOT00065039952; ENSRNOP00065032476; ENSRNOG00065023369.
DR   GeneID; 315599; -.
DR   KEGG; rno:315599; -.
DR   UCSC; RGD:1311293; rat.
DR   AGR; RGD:1311293; -.
DR   CTD; 79671; -.
DR   RGD; 1311293; Nlrx1.
DR   eggNOG; KOG4308; Eukaryota.
DR   GeneTree; ENSGT00940000159493; -.
DR   InParanoid; Q5FVQ8; -.
DR   OMA; NISMMKY; -.
DR   OrthoDB; 4044641at2759; -.
DR   Reactome; R-RNO-936440; Negative regulators of DDX58/IFIH1 signaling.
DR   Reactome; R-RNO-9758274; Regulation of NF-kappa B signaling.
DR   PRO; PR:Q5FVQ8; -.
DR   Proteomes; UP000002494; Chromosome 8.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0045824; P:negative regulation of innate immune response; ISO:RGD.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; ISO:RGD.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; ISO:RGD.
DR   GO; GO:0039536; P:negative regulation of RIG-I signaling pathway; ISO:RGD.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR051261; NLR.
DR   InterPro; IPR048900; NLRX1_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR24106; NACHT, LRR AND CARD DOMAINS-CONTAINING; 1.
DR   PANTHER; PTHR24106:SF152; NLR FAMILY MEMBER X1; 1.
DR   Pfam; PF13516; LRR_6; 1.
DR   Pfam; PF05729; NACHT; 1.
DR   Pfam; PF21402; NLRX1_C; 1.
DR   SMART; SM00368; LRR_RI; 6.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF52047; RNI-like; 1.
DR   PROSITE; PS50837; NACHT; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Host-virus interaction; Immunity; Innate immunity;
KW   Leucine-rich repeat; Membrane; Mitochondrion; Mitochondrion outer membrane;
KW   Nucleotide-binding; Reference proteome; Repeat; Transit peptide.
FT   TRANSIT         1..84
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000250"
FT   CHAIN           85..973
FT                   /note="NLR family member X1"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000296192"
FT   DOMAIN          158..481
FT                   /note="NACHT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
FT   DOMAIN          665..692
FT                   /note="LRRNT"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          693..716
FT                   /note="LRR 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          722..745
FT                   /note="LRR 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          747..775
FT                   /note="LRR 3"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          776..799
FT                   /note="LRR 4"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          809..832
FT                   /note="LRR 5"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          833..855
FT                   /note="LRR 6"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          856..875
FT                   /note="LRR 7"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REPEAT          876..897
FT                   /note="LRR 8"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   DOMAIN          904..968
FT                   /note="LRRCT"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REGION          73..554
FT                   /note="Required for interaction with MAVS"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   REGION          554..972
FT                   /note="Required for the repression of MAVS-induced
FT                   interferon signaling"
FT                   /evidence="ECO:0000250|UniProtKB:Q86UT6"
FT   BINDING         164..171
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00136"
SQ   SEQUENCE   973 AA;  107590 MW;  73B87B5A1B70DE9F CRC64;
     MRWGCHLPRT SWGSGLGRTV PLPDELRIQS SWPFKGVHHP LRPPRAFIRH HGNSADSAPP
     PGRHGQLFRS ISATEAIQRH RRNLTEWFSR LPREERQFGP TFALDTVHVD PVIRESTPDD
     LLRPSTELAT GHQRTQAELP PLALSQLFDP DACGRRVQTV VLYGTVGTGK STLVRKMVLD
     WCYGRLPAFE LLIPFSCEDL SSLGSTPASL CQLVTQRYTP LKEVLPLMNA AGSRLLFVLH
     GLERLNLDFR LAGTGLCSDP EEPGAPAAIM VNLLRKYMLP EASILVTTRP SAIGRIPSKY
     VGRYGEICGF SDTNLQKLYF QLRLNQPDCG YGAGGTGVSV TPAQRDNLIQ MLSRNLEGHH
     QIAAACFLPS YCWLVCATLH FLHAPTSAGQ TLTSIYTSFL RLNFNGETLD STDPSNLSLM
     SYAARTMGKL AYEGVSSRKT YFSEEDVRGC LEAGIKTEEE FQLLQIFRRD ALRFFLAPCV
     EPGHLGTFVF TVPAMQEYLA ALYIVLGLRK TALQRVGKEV FEFVGRVGED VSLVLGIVAK
     LLPLRILPLL FNLLKVVPRV FGRMVSKSRE AVAQAMVLEM FREEDYYNDD VLDQMGASIL
     GVEGPRRHPD EPPEDEVFEL FPMFMSGLLS AHNRAVLAQL GCPIKNLDAL ENAQAIKKKL
     GKMGRQVLPP SELLDHLFFH YEFQNQRFSA EVLGSLRQLN LAGVRMTPLK CTVVASVLGS
     GRHPLDEVNL ASCQLDPAGL HTLMPVLLRA RKLGLQLNNL GPEACRDLRD LLLHDQCQIT
     TLRLSNNPLT AAGVGVLMDG LAGNTSVTHL SLLHTDLGDE GLELLAAQLD RNKQLQELNV
     AYNGAGDTVA LALAKAARKH PSLELLHLYF NELSSEGRQV LRDLGGSGEG GARVVASLTE
     GTAVSEYWSV ILSEVQRNLN SWDPVRVQRH LKLLLRDLED SRGATLNPWR KAQLLRVESE
     VKTLLEQLGG SGH
//
